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Michigan; Layton, Utah; Munster, Indiana; Tupelo, Mississippi; and Chandler, ArizonaObjectives The ORBIT II (Evaluate the Safety and Efﬁcacy of OAS in Treating Severely Calciﬁed
Coronary Lesions) trial evaluated the safety and efﬁcacy of the coronary Orbital Atherectomy System
(OAS) to prepare de novo, severely calciﬁed coronary lesions for stent placement.
Background Despite advances in interventional techniques, treatment of calciﬁed coronary lesions
remains a challenge. Stent placement in these lesions may result in stent underexpansion,
malapposition, and procedural complications.
Methods ORBIT II is a prospective, multicenter, nonblinded clinical trial that enrolled 443 consecutive
patients with severely calciﬁed coronary lesions at 49 U.S. sites from May 25, 2010, to November 26,
2012. Investigators used the centrifugal action of the OAS diamond-coated crown to modify calciﬁed
lesions prior to stent placement.
Results The pre-procedure mean minimal lumen diameter of 0.5 mm increased to 2.9 mm after
the procedure. The primary safety endpoint was 89.6% freedom from 30-day major adverse cardiac
events compared with the performance goal of 83%. The primary efﬁcacy endpoint (residual stenosis
<50% post-stent without in-hospital major adverse cardiac events) was 88.9% compared with the
performance goal of 82%. Stent delivery occurred successfully in 97.7% of cases with <50% stenosis in
98.6% of subjects. Low rates of in-hospital Q-wave myocardial infarction (0.7%), cardiac death (0.2%),
and target vessel revascularization (0.7%) were reported.
Conclusions The ORBIT II coronary OAS trial met both the primary safety and efﬁcacy endpoints by
signiﬁcant margins. Preparation of severely calciﬁed plaque with the OAS not only helped facilitate
stent delivery, but improved both acute and 30-day clinical outcomes compared with the
outcomes of historic control subjects in this difﬁcult-to-treat patient population. (Evaluate the
Safety and Efﬁcacy of OAS in Treating Severely Calciﬁed Coronary Lesions [ORBIT II];
NCT01092416) (J Am Coll Cardiol Intv 2014;7:510–8) ª 2014 by the American College of
Cardiology Foundation
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511Despite advances in interventional equipment and tech-
niques, effective treatment for patients with severe coronary
calciﬁcation remains a challenge. Compared with non-
calciﬁed lesions, increased coronary arterial calcium deposi-
tion leads to a higher incidence of major adverse cardiac
events (MACE), in particular the rate of non–Q-wave
myocardial infarction (MI) (1). Calciﬁed lesions have been
shown to respond poorly to percutaneous coronary inter-
vention (PCI) and are associated with a high frequency of
restenosis, target lesion revascularization (TLR) (2), vessel
dissection during PCI (3), failure to deliver a stent (4),
balloon ruptures (5,6) and undilatable lesions (7,8). Up to
50% of coronary stents deployed in calciﬁed lesions were
found to have asymmetric stent expansion (9), potentially
increasing the likelihood of stent thrombosis and/or reste-
nosis (10). Attempts to remedy incomplete stent expansion
with aggressive high-pressure balloon dilation may result
in coronary artery rupture or dissection (11). Thus, severely
calciﬁed lesions are typically excluded from most trials.See page 519
and Acronyms
DES = drug-eluting stent(s)




MACE = major adverse
cardiac events
MI = myocardial infarction
OAS = Orbital Atherectomy
System
PCI = percutaneous coronary
intervention
RA = rotational atherectomy
TLR = target lesion
revascularizationAdditionally, given the difﬁculty in treating calciﬁc coronary
lesions percutaneously, these patients may be referred for
coronary artery bypass surgery. In the SYNTAX (Synergy
Between Percutaneous Coronary Intervention With Taxus
and Cardiac Surgery) trial, 32.7% of patients with previous
coronary artery bypass surgery were found to have heavily
calciﬁed lesions (12).
Coronary calciﬁcation is often underappreciated by con-
ventional angiography alone. Mintz et al. (13) studied 1,155
coronary native vessel target lesions (n ¼ 1,117). Calcium
was detected by angiography in 38% of lesions (26%
moderately, 12% severely calciﬁed), whereas intravascular
ultrasound (IVUS) showed 73% of lesions to have calcium
deposits, suggesting that coronary calciﬁcation is relatively
common (13). As IVUS is an underused diagnostic mo-
dality, coronary calciﬁcation is often underestimated or
considered mild or moderate via angiogram, when it may
actually be conﬁrmed as severe calciﬁcation if IVUS is used.From the *Metropolitan Heart and Vascular Institute, Mercy Hospital, Minneapolis,
Minnesota; yCentral Florida Heart Center, Ocala, Florida; zThe Stern Cardiovascular
Center, Memphis, Tennessee; xFlorida Heart Group, Orlando, Florida; kPalm Beach
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Memorial Medical Center, Daytona Beach, Florida; yyDesert Cardiology Center,
Rancho Mirage, California; zzThe Cardiac and Vascular Institute, Gainesville, Flor-
ida; xxIowa Heart Center, Des Moines, Iowa; kkComprehensive Cardiology Con-
sultants, Langhorne, Pennsylvania; {{Eastlake Cardiovascular Associates, St. Clair
Shores, Michigan; ##Utah Cardiology, Layton, Utah; ***Gessler Clinic, Winter Ha-
ven, Florida; yyyCardiology and Vascular Associates, Bloomﬁeld Hills, Michigan;
zzzLenox Hill Heart and Vascular Institute of New York, New York, New York;
xxxCardiology Associates of Northwest Indiana, Munster, Indiana; kkkCardiology
Associates of North Mississippi, Tupelo, Mississippi; and the {{{Premier
Cardiovascular Center, Chandler, Arizona. The ORBIT II trial was sponsored byFactors that lead to coronary calciﬁcation, such as dia-
betes, renal failure, and advanced age are on the rise (14–17).
Effective treatment strategies are needed if the growing
burden of calciﬁc coronary disease is to be mitigated. Prior
to approval by the U.S. Food and Drug Administration
(FDA) of the coronary Orbital Atherectomy System (OAS)
manufactured by Cardiovascular Systems, Inc. (CSI, St.
Paul, Minnesota) on October 21, 2013, the only treatment
option available for patients with severely calciﬁed coronary
lesions was rotational atherectomy (RA) even though RA
is not indicated by the FDA for that population of patients.
RA studies indicated improved procedural success in
severely calciﬁed lesions; however, its use has not led to a
reduction in restenosis (11).Methods
Device description. The coronary
OAS manufactured by CSI is
used to facilitate stent delivery in
patients with coronary artery dis-
ease who are acceptable candi-
dates for percutaneous transluminal
coronary angioplasty or stenting
due to de novo, severely calciﬁed
coronary artery lesions. Two OAS
conﬁgurations were used in the
ORBIT II (Evaluate the Safety
and Efﬁcacy of OAS in Treating
Severely Calciﬁed Coronary Le-
sions) study, pneumatic and elec-
tric OAS. A detailed discussion of
the novel use of centrifugal force
and differential sanding employed
by the coronary OAS to modify
calciﬁed coronary lesions was
previously described by Parikh et al. (18–20).
Study design and endpoints. ORBIT II, a prospective,
nonrandomized, single arm, multicenter study, was designed
to demonstrate: 1) OAS safety in de novo, severely calciﬁedCardiovascular Systems, Inc. Dr. Chambers receives consulting and presentation fees
from Cardiovascular Systems, Inc. (CSI), Vascular Solutions, Boston Scientiﬁc, and
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512coronary lesions; and 2) efﬁcacy of the OAS deﬁned as
successful stent delivery and deployment in severely calciﬁed
coronary lesions. The ORBIT II trial was conducted in the
United States per good clinical practice and the applicable
Code of Federal Regulations and the study was approved by
each institutional review/ethics committee. An angiographic
core laboratory (Cleveland Clinic Foundation, Cleveland,
Ohio) analyzed the procedural angiograms and reported the
minimum lumen diameter and ﬁnal percentage of residual
stenosis used for the primary efﬁcacy endpoint calculation, as
well as the presence and type of dissections and perforations.
Men and women, at least 18 years of age, with a clinical
indication for coronary intervention, who were found to have
a de novo, severely calciﬁed lesion in a native coronary artery
on ﬂuoroscopy or IVUS, were enrolled in the study after
meeting study selection criteria and providing informed
consent. Key study inclusion criteria included: 1) target
vessel reference diameter 2.5 mm and 4.0 mm with a
stenosis 70% and <100% or a stenosis 50% and <70%
with evidence of clinical ischemia via positive stress test, or
fractional ﬂow reserve value 0.8, or IVUS minimum lumen
area 4.0 mm2; 2) target lesion length 40 mm; 3) ﬂuo-
roscopic or IVUS evidence of severe calcium deposit at the
lesion site based on angiographic presence of radio-opacities
noted without cardiac motion prior to contrast injection
involving both sides of the arterial wall in at least one
location, total length of calcium of at least 15 mm and
extending partially into the target lesion, or presence of
270 of calcium at 1 cross section via IVUS. Patients were
excluded if any of the following applied: 1) the target vessel
had a stent from previous PCI unless the stent was on a
different branch than the target lesion and was implanted
more than 30 days before with no higher than 30% in stent-
restenosis; 2) they had a recent MI, deﬁned as creatine ki-
nase-myocardial band >1 upper limit of normal within 30
days prior to index procedure; 3) they were diagnosed with
chronic renal failure unless under hemodialysis, or had a
serum creatinine level >2.5 mg/dl; 4) there was evidence of
current left ventricular ejection fraction 25% (where cur-
rent is deﬁned as the latest left ventricular ejection fraction
measurement completed within the last 6 months).
Once the plaque was modiﬁed to improve vessel compli-
ance, the investigator was then required to implant the
FDA-approved stent(s) according to the manufacturer’s
instructions for use. Post-OAS/pre-stent and post-stent
percutaneous transluminal coronary angioplasty was
optional. There were no required/mandated medications in
the study. The use of thrombectomy therapy, an embolic
protection device, brachytherapy, or a cutting balloon was
not allowed. After ﬁnal treatment, the subjects were required
to complete an in-clinic visit at 30 days after the procedure
(between 30 and 44 days following OAS treatment).
Primary endpoint. The primary safety endpoint was to
demonstrate that the OAS is safe when used for stentdeployment in de novo, calciﬁed coronary lesions and was
measured by a composite of MACE at 30 days after the
procedure. MACE was deﬁned as comprising MI, target
vessel revascularization, and cardiac death. MI was deﬁned
as creatine kinase-myocardial band level >3 upper limit of
normal with or without a new pathologic Q-wave. Target
vessel revascularization was deﬁned as repeat revasculariza-
tion of the target vessel (inclusive of the target lesion) after
completion of the index procedure. The primary efﬁcacy
endpoint was deﬁned as procedural success deﬁned as stent
delivery with a residual stenosis of <50% without the
occurrence of an in-hospital MACE.
Secondary endpoint. The secondary endpoints included
angiographic success deﬁned as success in facilitating stent
delivery with a residual stenosis <50% without severe angio-
graphic complications during the index procedure as well as
the rate of individual severe angiographic complications
during the index procedure. Severe angiographic complica-
tions included severe dissections (types C to F), perforation,
persistent slow ﬂow, persistent no reﬂow, and abrupt closure.
Statistical analysis. The primary safety and efﬁcacy end-
points are based on comparisons to pre-speciﬁed perfor-
mance goals based on relevant published reports. Criteria
for relevant published reports included: English language
availability; calciﬁed lesions with and without pre-treatment
with atherectomy; in-hospital or 30-day MACE data;
publication later than 2000; and inclusion of 50 patients.
When the endpoint criteria were calculated, only 1 published
study (21) of a patient population (severely calciﬁed)
matched that of ORBIT II; therefore, papers reporting the
presence of calciﬁcation within a heterogeneous population
were included and adjusted for the approximate percentage
of severely calciﬁed lesions. One study segregated the
severely calciﬁed lesions (group F patients, >270 calcium)
from the rest of the population and was used to create the
adjustment factor for estimating the proportion of patients
with calciﬁed lesions in other studies as well as the adjust-
ment factor for the MACE rate for patients with severely
calciﬁed lesions (1). Relevant published data have shown that
the 30-day MACE rate ranged from 4.4% to 23.5%, with an
adjusted weighted mean MACE rate of 15.5% (1,21–24).
Adjustments to the published 30-day MACE rates were
done to derive estimates of the rates among a severely
calciﬁed lesion population. Weighting of the adjusted rates
was then done using the sample sizes of the studies. The
ORBIT II performance goal for the 30-day MACE rate was
conservatively set at 83%, allowing for some degree of vari-
ability due to sampling while still providing adequate power
based on expectations on the performance of the OAS sys-
tem. Based on the published reports, the adjusted weighted
mean procedural success rate was determined to be 84%;
therefore, a performance goal of 82% as the pre-deﬁned
study success criterion for the primary efﬁcacy endpoint was
chosen as conservative and clinically relevant (1,21,23–26).
Table 1. Baseline Characteristics




Black or African American 25/443 (5.6)
Asian 9/443 (2.0)
Hispanic or Latino 16/443 (3.6)
Native American 1/443 (0.2)
Other 3/443 (0.7)
eGFR, ml/min/1.73 m2, n ¼ 441 75.8
History of diabetes mellitus 160/443 (36.1)
History of dyslipidemia 407/443 (91.9)
History of hypertension 406/443 (91.6)
History of angina 348/443 (78.6)
Previous stroke/transient ischemic attack 39/443 (8.8)
Prior MI 99/443 (22.3)
Prior CABG 65/443 (14.7)
Smoker (current or former) 293/443 (66.1)
Values are n/N (%) unless otherwise indicated.
CABG ¼ coronary artery bypass graft; eGFR ¼ estimated glomerular ﬁltration rate;
MI ¼ myocardial infarction.
Table 2. Vessel and Lesion Characteristics
Target vessel
Left anterior descending artery 227/440 (51.6)
Left circumﬂex artery 64/440 (14.5)
Left main artery 10/440 (2.3)
Right coronary artery 132/440 (30.0)
Ramus 7/440 (1.6)
ACC/AHA lesion class
Type A 0/440 (0.0)
Type B1 114/440 (25.9)
Type B2 197/440 (44.8)
Type C 129/440 (29.3)
Mean lesion length, mm, n ¼ 440 18.9  0.4
Mean diameter stenosis, %, n ¼ 440 84.4  0.4
Mean reference vessel diameter, mm, n ¼ 440 3.1  0.0
Mean minimum lumen diameter, mm, n ¼ 440 0.5  0.0
Subjects with calciﬁcation determined by angiography only 405/440 (92.0)
Total length of calcium (including segmented), mm 28.6  0.8
Subjects with calcium visible on both sides of vessel 405/405 (100)
Subjects with calciﬁcation determined by IVUS 35/440 (8.0)
Maximum degree of calcium via IVUS 295.0  6.1
Values are n/N (%) or mean  SE.
ACC ¼ American College of Cardiology; AHA ¼ American Heart Association; IVUS ¼
intravascular ultrasound.
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513Kaplan-Meier analysis with a conﬁdence interval based on
Peto’s method was used for the primary safety endpoint and
an exact binomial conﬁdence interval for procedural success.
Descriptive statistics are provided for secondary endpoints.
The ORBIT II sample size was based on the primary
safety endpoint. A chi-square test was used to determine
the approximate sample size necessary to detect a clinically
meaningful change with approximately 80% power and
1-sided alpha-level of 0.025. Adjusting for a 5% rate of
attrition and missing data at 30 days after the procedure,
it was determined that enrollment of 429 subjects would
be required. The overall study sample size was increased to
479 subjects to ensure the inclusion of 100 subjects treated
with the electric OAS.
Statistical analyses were performed with either SAS
software system (SAS Institute Inc., Cary, North Carolina)
or R (R Core Team 2012, R Foundation for Statistical
Computing, Vienna, Austria). Patient demographics, med-
ical history, risk factors, pre- and post-procedure lesion
characteristics, procedure characteristics, and outcome vari-
ables were summarized using descriptive statistics for
continuous variables presented as mean  SE and frequency
tables or proportions for discrete variables.
Results
Patient demographics and lesion characteristics. The
ORBIT II study population consisted of 443 patients
enrolled at 49 sites in the United States. Of the 443 subjects
enrolled, 3 subjects were immediately withdrawn from the
study (the OAS device was never inserted) because 2 of them
no longer met all angiographic criteria following insertion of
the study guidewire (ViperWire, CSI, St. Paul, Minnesota)
and 1 subject was prepped with a 6-F sheath that did not
allow for the introduction of the OAS per the instructions
for use. The OAS device was inserted in 440 subjects and
crossed the lesion in 432 subjects. In 2 cases, the OAS
device was activated but could not cross the lesion. Patient
demographics are presented in Table 1. Subjects enrolled in
the ORBIT II study demonstrated a high number of risk
factors for coronary disease consistent with advanced
atherosclerotic disease such as diabetes and previous CABG.
Target vessel and lesion characteristics, including angio-
graphic determination of pre-procedure percentage of ste-
nosis are reported in Table 2. Minimum lumen diameter was
calculated from the percentage of stenosis and reference
vessel diameter in all cases. Vessel calciﬁcation (determined
by angiography) is reported in Table 2. For the majority
of subjects (92%), angiography determined the calciﬁcation
of the target vessel.
Procedural results. Procedural results are listed in Table 3.
Table 4 summarizes the overall procedural results using
the OAS, and Table 5 summarizes the OAS treatment
parameters.Primary safety endpoint. The 30-day MACE components
are presented in Table 6. At 30 days after the index pro-
cedure, MACE occurred in 46 subjects. The null hypothesis
was to be rejected in favor of the alternative if the lower
2-sided 95% conﬁdence bound for the MACE-free rate was
>83% (Fig. 1). All subjects for whom the guidewire crossed
Table 3. Overall Procedural Results
Subjects treated with pre-OAS balloon dilations 8/440 (1.8)
Subjects treated with post-OAS/pre-stent balloon dilations 181/440 (41.1)
Maximum inﬂation pressure, atm, n ¼ 180 12.1  0.3
Mean post-OAS balloon angioplasty residual
stenosis, %, n ¼ 179
42.4  1.5
Subjects with stent placed 432/440 (98.2)
Post-OAS stents used per subject, n ¼ 432 1.3  0.0




Maximum deployment pressure, atm, n ¼ 430 13.8  0.2
Post-stent residual stenosis, %, n ¼ 431 5.8  0.6
Subjects treated with post-stent balloon angioplasty 227/440 (51.6)
Mean post-stent balloon angioplasty residual
stenosis, %, n ¼ 223
1.1  0.2
Values are n/N (%) or mean  SE.
BMS ¼ bare-metal stent(s); DES ¼ drug-eluting stent(s); OAS ¼ Orbital Atherectomy System.
Table 5. OAS Treatment Parameters
Subjects where OAS device was inserted, n 440
Subjects treated with OAS device, n 432
OAS device used
Pneumatic, 1.25 mm 320/457 (70.0)
Pneumatic, 1.50 mm 33/457 (7.2)
Pneumatic, 1.75 mm 2/457 (0.4)
Pneumatic, 2.00 mm 2/457 (0.4)
Electric, 1.25 mm 98/457 (21.4)
Electric, 1.50 mm 2/457 (0.4)
OAS devices used per subject, n ¼ 432 1.1  0.0
OAS device speed(s) used, revolutions/min
Low only, 80,000 93/432 (21.5)
Low and high, 80,000 and 120,000 317/432 (73.4)
High only, 120,000 22/432 (5.1)
Total OAS device run time, s, n ¼ 431 66.8  2.2
Average individual OAS run time, s, n ¼ 430 19.5  0.3
Post-OAS residual stenosis, %, n ¼ 432 58.7  0.8
Values are n/N (%) or mean  SE unless otherwise indicated.
OAS ¼ Orbital Atherectomy System.
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514the lesion have been included in the primary safety endpoint
analysis (n ¼ 443). As shown in Figure 1, the observed
freedom from 30-day MACE was 89.6%, with a 2-sided
conﬁdence interval of 86.7% to 92.5%. Greater than the
pre-deﬁned performance goal of 83%, this lower bound of
86.7% indicates the goal was met successfully.
Primary efﬁcacy endpoint. Successful stent delivery and
<50% residual stenosis occurred in 97.7% and 98.6% of
subjects, respectively. In-hospital MACE occurred in 43
subjects (9.8%), and the individual components of in-
hospital MACE are presented in Table 6. The null hy-
pothesis was to be rejected in favor of the alternative if the
lower 2-sided 95% conﬁdence bound for the primary efﬁcacy
rate was greater than the performance goal of 82% (Fig. 2).
Only subjects treated by the OAS (the guidewire crossed
the lesion and OAS device was inserted) have been included
in the primary efﬁcacy endpoint analysis (n ¼ 440). As
presented in Figure 2, the observed rate of procedural suc-
cess was 88.9% with a 2-sided conﬁdence interval of 85.5%
to 91.6%. Greater than the pre-deﬁned performance goal of
82%, this lower bound of 85.5% indicates the goal was met
successfully.Table 4. Final Overall Procedural Results
Total procedure time, min,* n ¼ 439 52.5  1.4
Total ﬂuoroscopy time, min, n ¼ 436 18.2  0.6
Total volume of contrast used, ml, n ¼ 438 173.9  4.1
Final procedure minimum lumen diameter,y mm, n ¼ 425 2.9  0.0
Final procedure stenosis,y %, n ¼ 439 4.7  0.7
Values are mean  SE. *Total procedure time deﬁned as the time from when the ﬁrst guide
catheter was placed in the access site to the time the last guide catheter was removed from
the access site. yMinimum lumen diameter and ﬁnal procedure stenosis were assessed by the
angiographic core laboratory.Secondary endpoints. Angiographic success was achieved in
91.4% (405 of 443) of subjects and severe angiographic
complications occurred at a rate of 7.2% (32 of 443 subjects).
Angiographic success results were similar for the pneumatic
and electric OAS versions of the device, with rates of 91.0%
(312 of 343) and 93.0% (93 of 100), respectively. The rate of
severe angiographic complications was similar for the
pneumatic and electric OAS devices with a nominally lower
rate for the electric OAS (5.0% vs. 7.9% for pneumatic
OAS). Some subjects may have failed >1 component of the
angiographic success criteria, and, therefore, the categories
are not mutually exclusive. Severe angiographic complica-
tions are listed in Table 7.Discussion
Coronary lesions with severe (or heavy) calciﬁcation are
classiﬁed as complex lesions and are known to carry lower




MACE rate 9.8 10.4
Cardiac death 0.2 0.2
Non–Q-wave MI 8.6 8.8
Q-wave MI 0.7 0.9
TVR 0.7 1.4
Values are %.
MACE ¼ major adverse cardiac events; MI ¼ myocardial infarction; TVR ¼ target vessel
revascularization.








(type C, D, E, and F)
0.2 2.3 0.9 0.0 15/443 (3.4)
Perforation 0.0 0.9 0.9 0.0 8/443 (1.8)
Persistent slow ﬂow 0.2 0.2 0.5 0.0 4/443 (0.9)
Persistent no reﬂow 0.0 0.0 0.0 0.0 0/443 (0.0)
Abrupt closure 0.2 0.9 0.2 0.5 8/443 (1.8)
Values are % or n/N (%).
OAS ¼ Orbital Atherectomy System.
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515than do noncalciﬁed or mildly calciﬁed lesions (1,3,6,21,27).
Severe calcium also poses technical challenges during PCI,
resulting in stent underexpansion, malapposition, or the
inability to place a stent (1,4). Extensive calcium may
damage the polymer coating of drug-eluting stents (DES)
(28,29) and, therefore, contribute to the ineffectiveness of
DES when implanted into such lesions (30). As a result,
calciﬁcation has been an exclusion criterion for almost all
large-scale PCI studies, and there were no FDA-approved
percutaneous treatments speciﬁcally for patients with
severely calciﬁed coronary lesions prior to the FDA approval
of the OAS device. ORBIT II met its primary safety and
efﬁcacy study endpoints as a lesion preparation tool prior to
stent placement in this patient population.Figure 1. Primary Safety Endpoint
The observed freedom from 30-day major adverse cardiac event (MACE) was 89.6%
pre-deﬁned performance goal of 83%, this lower bound of 86.7% indicates the goal
ps ¼ probability of freedom from MACE within 30 days post procedure.The ORBIT II trial is the largest series to date reporting
exclusively on patients with severely calciﬁed lesions. The
ORBIT II trial found a high rate of successful stent delivery
(97.7%) and residual stenosis <50% (98.6%) with a low
angiographic complication rate. The incidence of slow
ﬂow and no reﬂow were notably very low, occurring in <1%
of patients. This is in contrast to Japanese RA studies
showing a range of 0% to 18% (31–34). The ORBIT II
dissection (types C to F) rates for post-OAS device and ﬁnal
were 2.3% and 3.4%, respectively. A review of the published
reports found 7 studies using RA that reported types C to F
dissection rates ranging from 2.1% to 8.4% (32,35–40).
The ORBIT II trial had among the lowest rates for this
complication. Similarly, abrupt closure occurred in 0.9%, with a 2-sided conﬁdence interval (CI) of 86.7% to 92.5%. Greater than the
was met successfully. HA ¼ alternative hypothesis; Ho ¼ null hypothesis;
Figure 2. Primary Efﬁcacy Endpoint
The observed rate of procedural success was 88.9%, with a 2-sided conﬁdence interval of 85.5% to 91.6%. Greater than the pre-deﬁned performance goal of
82%, this lower bound of 85.5% indicates the goal was met successfully. OAS ¼ Orbital Atherectomy System; ps ¼ probability of procedural success; other
abbreviations as in Figure 1.
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516(post-OAS device) and 1.8% (ﬁnal) of patients in the cur-
rent study compared with rates from 1% to 4% in 6 studies
that reported abrupt closure during RA (34–37,40,41).
Perforations occurred in 0.9% (post-OAS device) and 1.8%
(ﬁnal) of patients compared with 0.4% to 2.5% in the 10 RA
studies reporting on this complication (4,32,34–37,39–42).
The post-OAS device perforation rate is at the low end of
the previously reported range and the ﬁnal ORBIT II
perforation rate is within the range.
ORBIT II reported much lower in-hospital rates of non–
Q-wave and Q-wave MI at 8.6% (38 of 440) and 0.7% (3
of 440), respectively, than did previous studies evaluating
coronary calciﬁed lesions. For example, Mosseri et al. (1)
evaluated the effect of coronary calciﬁcation on non–Q-wave
MI in patients treated with RA and bare-metal stents. They
demonstrated signiﬁcant increases in non–Q-wave MI rates
corresponding to the increase of calcium arc via IVUS:
20.9% (>270 of calcium group) compared with 8.0% (0 to
90 of calcium group). Clavijo et al. (21), among the very
few trials that studied severely calciﬁed lesions treated with
DES with and without RA, found a non–Q-wave MI
(creatine kinase-myocardial band elevation >3 upper limit
of normal) rate of 19.8% in the RAþDES group and a
25.8% rate in the DES-only group. They also reported an
in-hospital Q-wave MI rate for RAþDES group at 1.3%.There are only a few previous studies that reported TLR
and death rates for patients with severely calciﬁed coronary
arteries. Mosseri et al. (1) reported an in-hospital TLR rate
and death rate of 1.6% each. Clavijo et al. (21) reported a
30-day TLR rate of 1.3% and a death rate of 2.6% for the
RAþDES group. In contrast, the ORBIT II study reported
a lower in-hospital TLR rate of 0.7% and a much lower
cardiac death rate of 0.2%.
Study limitations. This study lacked a control arm. Even
though coronary atherectomy is a known technology with
several products already approved by the FDA, none of these
were previously indicated for severely calciﬁed coronary
arteries and, therefore, could not be used as a control. This
was mitigated by comparison to historical control subjects
documented in published reports. Although this is a sig-
niﬁcant limitation, it is important to note that the ORBIT II
study was a prospective, multicentered, core lab adjudicated
trial that was successful in exceeding its primary endpoints
by a signiﬁcant margin in a difﬁcult-to-treat patient popu-
lation that is typically excluded from clinical trials.
Conclusions
Preparation of severely calciﬁed plaque with OAS not only
helped facilitate stent delivery, but also improved both acute
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517and 30-day clinical outcomes when compared with historic
control subjects in this difﬁcult-to-treat patient population.
The primary safety endpoint was 89.6% freedom from
30-day MACE compared with its performance goal of 83%.
The primary efﬁcacy endpoint (residual stenosis <50% post-
stent without in-hospital MACE) was 88.9% compared
with the performance goal of 82%. Stent delivery occurred
successfully in 97.7% and <50% stenosis in 98.6% of sub-
jects. The OAS is a technology that appears to address the
unmet medical need to treat patients with severely calciﬁed
coronary lesions. Using the OAS as a lesion preparation tool
prior to stent deployment may offer patients with severely
calciﬁed coronary lesions a new treatment option.
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